Document is current

Article History

Received: 17 July 2019

Accepted: 9 September 2019

First Online: 20 September 2019

Compliance with ethical standards

:

: Ali Pirasteh: Nothing to disclose. Christopher Riedl: Nothing to disclose. Marius Erik Mayerhoefer: Speaker honoraria from Siemens Healthcare and Bristol-Myers Squibb and research support from Siemens Healthcare. Romina Grazia Giancipoli: Nothing to disclose. Steven Mark Larson: receiving commercial research grants from Genentech, Inc., WILEX AG, Telix Pharmaceuticals Limited, and Regeneron Pharmaceuticals, Inc.; holding ownership interest/equity in Voreyda Theranostics Inc. and Elucida Oncology Inc., and holding stock in ImaginAb, Inc. SML is the inventor and owner of issued patents both currently unlicensed and licensed by MSK to Samus Therapeutics, Inc., Y-mAbs Therapeutics Inc., and Elucida Oncology, Inc. SML is or has served as a consultant to Cynvec LLC, Eli Lilly & Co., Prescient Therapeutics Limited, Advanced Innovative Partners, LLC, Gerson Lehrman Group, Progenics Pharmaceuticals, Inc., and Janssen Pharmaceuticals, Inc. Lisa Bodei: Consultancy and speaker for AAA and Ipsen; consultancy for Curium.

: This review article does not contain any imaging studies with human or animal subjects performed by the authors solely for the purposes of this review. The provided images are from exams performed for the purposes of clinical care at the authors’ institution (Memorial Sloan Kettering Cancer Center), and not with the prospective intention of being utilized for this review. No Institutional Review Board approval or patient consent was required for the purposes of this literature review. All patient information was handled according the United States Health Insurance and Accountability Act.